Aug 26 (Reuters) – Biohaven has entered into a licensing agreement with South Korean drug maker SK Biopharmaceuticals for Biohaven’s epilepsy drug platform, including Opakalim, for up to $795 million, the companies said in a statement on Wednesday.
(Reporting by Anusha Shah in Bengaluru; Editing by Sonia Cheema)
Comments